Tilray: Fourth Quarter Consensus Estimates

Tilray (TSX: TLRY) (NASDAQ: TLRY) will be reporting its fourth quarter financial results on July 28 before the market opens. Analysts have a consensus $17.77 12-month price target on the company, via a total of 20 analysts, with 2 analysts having strong buy ratings. 3 analysts meanwhile have buy ratings, 14 have hold ratings and a single analyst has a sell rating on the company. The street high comes from Roth Capital with a $25 price target, and the lowest target sits at $1.27 from GLJ Research.

10 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 10 analysts is $146.19 million; this number has been revised upwards from $71.20 million at the start of the year. The highest revenue estimate is $175.4 million, while the lowest is $107.62 million.

Onto EBITDA estimates, there are currently 7 analysts who have fourth-quarter EBITDA estimates. The mean is currently $5.81 million, with this number being flat since the start of the year. The street high estimate currently sits at $11.7 million in EBITDA and the lowest is -$2.83 million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A Copper-Gold Deposit Caught the White House’s Attention | Rob McLeod – Cambria Gold

Why Discipline Matters in a High Gold Price Market | Darren Hall – Equinox Gold

This Copper Junior Just Secured $96 Million | Simon Quick – Canadian Copper

Recommended

Antimony Resources Drills 4.38% Sb Over 7.05 Metres At Bald Hill In Final Hole Of 2025 Program

Kirkland Lake Drills 121 Metres Of 1.01 g/t Gold At Mirado

Related News

Aphria Posts Revenues of $126.11 Million for First Quarter 2020

Aphria Inc (TSX: APHA) (NYSE: APHA) announced this morning revenues of $126.11 million, a decline...

Tuesday, October 15, 2019, 08:28:58 AM

Canaccord Drops Medmen Price Target To $0.00, Reiterates Sell Rating

After Medmen Enterprises’ (CSE: MMEN) fourth-quarter results dropped after hours on October 15th, Canaccord downgraded...

Friday, October 16, 2020, 12:22:53 PM

Trulieve: Canaccord Reiterates $97 Price Target Following First Quarter Results

Trulieve Cannabis (CSE: TRUL) reported its first-quarter financial results on May 13th, beating the analyst...

Sunday, May 16, 2021, 03:27:00 PM

Alphabet: BMO Raises Price Target To $2,700 Following Exceptional Earnings

Alphabet (NASDAQ: GOOG) reached record highs this week after its first-quarter results blew investors away,...

Friday, April 30, 2021, 11:38:00 AM

CIBC: Cronos Group CEO Switch Up Is “Somewhat Surprising”

This past week, Cronos Group (TSX: CRON) (NASDAQ: CRON) announced that its Board of Directors...

Saturday, September 12, 2020, 01:45:00 PM